Tighter oversight of manufacturers pricing policies and the competitive environment Its unseemly (polite word choice) that the CEO of Lilly, Dave Ricks, is able to rake in total compensation of $114 million in 2024 while at the same time acknowledging that the price his company charges for Zepbound is too high. Unseemly, because his payday was fueled by Lilly making more than $10 billion in profit from GLP-1s in 2024 alone
Clinical research priorities include properly designed human clinical trials with adequate sample sizes, appropriate controls, and validated outcome measures
The current challenge is not inducing further loss, but preventing weight regain
Curr Protein Pept Sci 20:907917 Shi Y, Wu W, Yang Y, Liu X, Lin J, Liu X (2023) Gene knockout of glutathione reductase results in increased sensitivity to heavy metals in Acidithiobacillus caldus
Reading through our detailed aesthetic dermatology blog updates can help clarify many such prevalent industry rumors and protect your health
Recognizing the value of your time, Rev(IV)al Hydration brings its top-notch Mobile IV Therapy in Palo Alto services directly to you
